E-MERCK
Article Abstract:
E-Merck posted a net profit of Rs194.80 million for the year ended December 1997. E-Merck AG, Germany holds 51 percent stake in E-Merck. The company manufactures vitamins for therapeutic purposes. Polybion, Evion and Neurobion account for 70 percent of its formulations sales. It also manufactures cardiac care products like Depicor, Isocor, Concor and Myoace. It is likely to post a sales growth of 12-15 percent in the next two to three years. (rk) ------------------------------------------------------------ Financial Performance of E-Merck (Rs in million) ------------------------------------------------------------ Particulars Year ended December 1997 ------------------------------------------------------------ Sales 2,221.30 ------------------------------------------------------------ Gross profit 426.30 ------------------------------------------------------------ Net profit 194.80 ------------------------------------------------------------ Equity 168.60 ------------------------------------------------------------ Earnings per share (Rs) 11.60 ------------------------------------------------------------ Market price of share (Rs) 267.80 ------------------------------------------------------------
Comment:
Posts a net profit of Rs194.80 mil on sales of Rs2,221.30 mil for the year ended 12/97
Publication Name: Financial Express Investment Week
Subject: Business, international
ISSN: 0015-2005
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
NOVARTIS INDIA: A REVIEW
Article Abstract:
Novartis India is a 51 percent subsidiary of Novartis of Switzerland. Novartis India has 5 divisions - pharmaceuticals, crop protection, seeds, animal health and Ciba vision. Its pharmaceutical division focuses on formulations. It is setting up manufacturing facilities in Goa for profenophos formulations. Its crop protection division makes fungicides, herbicides and insecticides. Its pharmaceutical and crop protection businesses contribute 90 percent to the total sales of Novartis India. It has tied up with Pharmacia and Upjohn for marketing Litalyse injections. It recorded a growth of 16.6 percent in sales at Rs390.5 crore and 104.5 percent in its net profit at Rs31.9 crore in the first half of 1998-99. Its operating profit margin was 15.1 percent. (rk/kvr)
Publication Name: Financial Express Investment Week
Subject: Business, international
ISSN: 0015-2005
Year: 1999
User Contributions:
Comment about this article or add new information about this topic:
GANESH BENZOPLAST GROUP: "DANDI MARCH" SANS SALT!
Article Abstract:
The Ganesh Benzoplast Group has entered the capital market four times between January 1987 and January 1995, along with two rights and two private placements, and has mobilised Rs2467.9 million from its various issues. The group had accumulated reserves of Rs50 million at the time of its last premium issue in January 1995. The group consists of Ganesh Benzoplast Ltd (GBL) and Ganesh Anhydride Ltd (GAL). GBL had projected a turnover of Rs1561.1 million in 1996-97 against which it managed a turnover of Rs805.7 million. Its scrip has fallen to Rs13 at present from about Rs145 in January 1995. (khr)
Publication Name: Financial Express Investment Week
Subject: Business, international
ISSN: 0015-2005
Year: 1998
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: WORRISOME FISC. CALL RATE REMAIN STEADY. Rs4,000-CR GILTS AUCTION SEES SALE OF ONLY Rs 50 L
- Abstracts: LES SENIORS EN EUROPE LIVRAISONS A DOMICILE PME sous pression
- Abstracts: TATA CHEMICALS NAGARJUNA FERTILIZERS AND CHEMICALS LIMITED. SWC BOARD RECAST, KOMAL WAZIR MADE DIRECTOR
- Abstracts: SMITHKLINE BEECHAM PHARMACEUTICALS (INDIA) SMITHKLINE BEECHAM PHARMACEUTICALS
- Abstracts: LUPIN LABORATORIES LTD DHARAMSI MORARJI CHEMICALS: CORE COMPETENCIES?